Abstract: Provided are methods for the treatment of spinal muscular atrophy (SMA) in a fetal subject in need thereof comprising administering an amount of risdiplam to a carrier of the fetal subject. Administering the amount of risdiplam to the carrier of the fetal subject results in transplacental delivery to the fetal subject, resulting in an increase in SMN protein production.
Type:
Application
Filed:
October 13, 2023
Publication date:
May 30, 2024
Applicants:
Genentech, Inc., Hoffmann-La Roche Inc.
Inventors:
Richard S. Finkel, Heidemarie Kletzl, Lutz Mueller, Renata Siciliani Scalco, Gaurav Seth, Alexander Herbert Stephan
Abstract: Disclosed are 2,8-diazaspiro[4.5]decane compounds, including (pyrido[3,4-d]pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane compounds, (2,6-naphthyridin-1-yl)-2,8-diazaspiro[4.5]decane compounds, and (1,7-naphthyridin-4-yl)-2,8-diazaspiro[4.5]decane compounds, that are inhibitors of LATS1/2, compositions containing these compounds, and methods for inhibiting LATS1/2 activity.
Type:
Application
Filed:
December 1, 2023
Publication date:
May 30, 2024
Applicant:
Genentech, Inc.
Inventors:
Steven John MCKERRALL, Alice Rose WONG, James John CRAWFORD, Wendy LEE, Kwong Wah LAI, Guillaume PELLETIER, Stéphanie ROY, Dana Krystin WINTER, Mikiko OKUMURA, Ruth Dorel
Abstract: Provided herein are combination therapies comprising GDC-9545 and a CDK4/6 inhibitor for treating locally advanced breast cancer or metastatic breast cancer.
Type:
Application
Filed:
January 26, 2024
Publication date:
May 30, 2024
Applicant:
Genentech, Inc.
Inventors:
Jennifer O'Hara LAUCHLE, Sandra MILAN, Melanie Carol SMITT, Marjorie C. GREEN
Abstract: The present disclosure relates to compounds and salts thereof that are useful for modulating target polypeptides and proteins, in particular BRM. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various BRM-mediated and/or BRG1-mediated diseases or disorders.
Type:
Grant
Filed:
August 8, 2022
Date of Patent:
May 28, 2024
Assignee:
GENENTECH, INC.
Inventors:
Elisia Villemure, Joachim Rudolph, Mingshuo Zeng
Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.
Type:
Grant
Filed:
July 9, 2021
Date of Patent:
May 28, 2024
Assignees:
Genentech, Inc., Hoffmann-La Roche Inc.
Inventors:
Mark C. Benyunes, Graham Alexander Ross
Abstract: Methods of making benzoxazepin oxazolidinone compounds as well as synthetic intermediates are described, including compound (10-2) and compound 18:
Type:
Application
Filed:
November 27, 2023
Publication date:
May 23, 2024
Applicant:
Genentech, Inc.
Inventors:
Rémy Angelaud, Tobias Bruetsch, Francis Gosselin, Chong Han, Alfred Stutz
Abstract: The present disclosure relates to highly sensitive methods for determining the identity and quantity of one or more proteins in a sample. For example, the present disclosure provides methods for the highly sensitive identification and quantitation of residual host cell proteins in protein samples and can be adapted to identify and quantify proteins in either a targeted or a target-agnostic manner and can be modified to achieve a range of sensitivities appropriate for distinct use cases.
Type:
Application
Filed:
December 1, 2023
Publication date:
May 23, 2024
Applicants:
GENENTECH, INC., HOFFMANN-LA ROCHE INC.
Inventors:
Jia Guo, Regina Kufer, Delia Li, Feng Yang, Inn Huam Yuk, Jinhua Zhang, Lance J. Cadang, Lu Dai
Abstract: The invention concerns methods for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
Type:
Grant
Filed:
January 11, 2024
Date of Patent:
May 21, 2024
Assignee:
Genentech, Inc.
Inventors:
Yung-Hsiang Kao, Michael W. Laird, Melody Trexler Schmidt, Rita L. Wong, Daniel P. Hewitt
Abstract: The invention concerns methods for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
Type:
Grant
Filed:
January 11, 2024
Date of Patent:
May 21, 2024
Assignee:
Genentech, Inc.
Inventors:
Yung-Hsiang Kao, Michael W. Laird, Melody Trexler Schmidt, Rita L. Wong, Daniel P. Hewitt
Abstract: The present invention contemplates a method of producing a recombinant protein comprising (a) fermenting a prokaryotic host cell wherein said prokaryotic host cell has been transformed with a nucleic acid encoding said recombinant protein, and (b) harvesting said recombinant protein under conditions where dO2 levels are greater than 0%, and (c) purifying said recombinant protein to a filtered bulk, wherein said filtered bulk does not contain detectable DHNA-recombinant protein adduct, as measured by an IEC assay at 310 nm.
Type:
Application
Filed:
January 22, 2024
Publication date:
May 16, 2024
Applicant:
Genentech, Inc.
Inventors:
Michael W. LAIRD, Richard ST. JOHN, Jane V. GUNSON, Kimberly KALEAS, Deepa NADARAJAH, Rachel L.E. ADAMS, Bradley R. SNEDECOR
Abstract: Described herein are Fc variants and methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins). Heteromultimeric proteins may be capable of specifically binding to more than one target. The targets may be, for example, different epitopes on a single molecule or located on different molecules. The methods combine efficient, high gene expression level, appropriate assembly, and ease of purification for the heteromultimeric proteins. The invention also provides methods of using these heteromultimeric proteins, and compositions, kits and articles of manufacture comprising these antibodies.
Abstract: The invention concerns methods and means for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
Type:
Application
Filed:
January 11, 2024
Publication date:
May 16, 2024
Applicant:
Genentech, Inc.
Inventors:
Yung-Hsiang KAO, Michael W. LAIRD, Melody Trexler SCHMIDT, Rita L. WONG, Daniel P. HEWITT
Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.
Type:
Application
Filed:
November 13, 2023
Publication date:
May 9, 2024
Applicant:
Genentech, Inc.
Inventors:
Paul Gibbons, Emily Hanan, Wendy Liu, Joseph Lyssikatos, Steven R. Magnuson, Rohan Mendonca, Richard Pastor, Thomas E. Rawson, Michael Siu, Mark E. Zak, Aihe Zhou, Bing-Yan Zhu, Christopher Hurley
Abstract: The invention concerns methods and means for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
Type:
Application
Filed:
January 11, 2024
Publication date:
May 9, 2024
Applicant:
Genentech, Inc.
Inventors:
Yung-Hsiang KAO, Michael W. LAIRD, Melody Trexler SCHMIDT, Rita L. WONG, Daniel P. HEWITT
Abstract: The invention provides anti-KLK7 antibodies, anti-KLK5 antibodies, anti-KLK5/KLK7 multispecific antibodies, and methods of using the same.
Type:
Application
Filed:
December 19, 2023
Publication date:
May 9, 2024
Applicant:
Genentech, Inc.
Inventors:
James Thomas KOERBER, Wyne Pun LEE, Tangsheng YI, Juan ZHANG, Cary Dean AUSTIN, Cecilia P.C. CHIU, Joseph Edward CHAVARRIA-SMITH, Jawahar SUDHAMSU
Abstract: The invention concerns methods and means for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
Type:
Grant
Filed:
April 20, 2023
Date of Patent:
May 7, 2024
Assignee:
Genentech, Inc.
Inventors:
Yung-Hsiang Kao, Michael W. Laird, Melody Trexler Schmidt, Rita L. Wong, Daniel P. Hewitt
Abstract: The present invention relates to pharmaceutical compositions comprising Akt protein kinase inhibitors with therapeutic activity against diseases such as cancer as well as processes for their preparation and their use as medicament.
Type:
Grant
Filed:
April 19, 2022
Date of Patent:
April 30, 2024
Assignee:
Genentech, Inc.
Inventors:
Reinhard Reents, Pirmin Hidber, Andre Hell, Peter Steidle, Martin Wunderlich, Marie Pepelnjak, Francis Gosselin, Edward Yost
Abstract: The invention concerns methods and means for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
Type:
Application
Filed:
April 20, 2023
Publication date:
April 25, 2024
Applicant:
Genentech, Inc.
Inventors:
Yung-Hsiang Kao, Michael W. Laird, Melody Trexler Schmidt, Rita L. Wong, Daniel P. Hewitt
Abstract: The present disclosure relates to techniques for segmenting objects within medical images using a deep learning network that is localized with object detection based on a derived contrast mechanism. Particularly, aspects are directed to localizing an object of interest within a first medical image having a first characteristic, projecting a bounding box or segmentation mask of the object of interest onto a second medical image having a second characteristic to define a portion of the second medical image, and inputting the portion of the second medical image into a deep learning model that is constructed as a detector using a weighted loss function capable of segmenting the portion of the second medical image and generating a segmentation boundary around the object of interest. The segmentation boundary may be used to calculate a volume of the object of interest for determining a diagnosis and/or a prognosis of a subject.
Type:
Grant
Filed:
February 7, 2022
Date of Patent:
April 23, 2024
Assignee:
Genentech, Inc.
Inventors:
Luke Xie, Kai Henrik Barck, Omid Bazgir